Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Teva names new CEO after seven-month hunt

September 11, 2017 11:19 PM UTC

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) jumped on Monday after naming Kåre Schultz president and CEO. Teva gained $3 (19%) to $18.50 in New York and NIS9.06 (17%) to NIS63.55 in Tel Aviv.

Teva has been seeking a new CEO since Erez Vigodman resigned in February. It also continues to search for a new CFO since Eyal Desheh announced his resignation in April (see BioCentury Extra, Feb. 6 & April 26)...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article